Referring to the steps taken by the Iranian Health Ministry in line with supplying foreign vaccines, president said Iran has had a successful performance in producing domestic vaccines and supplying foreign ones.

Phase 2 and 3 of a clinical trial for the first Iranian coronavirus vaccine, COVIran Barakat, began on Monday with two voluntary receivers.

The first phase of the COVIran Barakat test was carried out early in January and 56 volunteers at the age of 18-50 received two doses of the vaccine.

The collection of blood samples from phase one volunteers completed last week and the final report was handed over to Iran’s Health Ministry.

Yesterday, Speaking at the unveiling ceremony of the Sepand vaccine, Namaki said that it was the product of a project commenced by Mohsen Fakhrizadeh, the nuclear scientist assassinated by agents of the Zionist Regime in November.

Namaki is going to give more details about the Sepand vaccine on Tuesday when the clinical trial will begin.

In addition to Sepand, three other COVID-19 vaccine projects in Iran have begun their clinical trial. Razi Serum Production Institute and Execution of Imam Khomeini’s Order are two Iranian institutes that are working on the vaccine, as well as the Soberana-01 vaccine of Cuba which began a clinical trial in Iran.

In the ceremony, spokesman for headquarters for the fight against the coronavirus Alireza Raisi said that 1,260,000 doses of different coronavirus vaccines have so far been imported in order to vaccinate over 1 million people working as healthcare personnel in the coming weeks.

The post President lauds supplying COVID19 vaccine in Iran appeared first on Iran News Daily.

He further hailed the close cooperation among ministries of health, agricultural Jihad, and the Central Bank of Iran (CBI) in this program and hoped that by the end of the last human testing phase, the launching of the mass production line of the vaccine, too, will take place.

The professor said that prior to the human testing phases, this vaccine was tested on a large number of animals, with very satisfactory results, and hoped the same results will be achieved in the last phase of its human testing.

According to the official, 133 people volunteered in the 1st phase of the human trial phase, 13 of whom received the vaccine initially while the rest had it according to a gradual time schedule.

“The next phase started a week later on a larger group, subdivided into four test groups, and 23 days’ time-lapse was given in this phase, after which the smelling phase of the vaccine began 30 days later,” said Dr. Fallah.

He said that after the successful end of that first phase and receiving the approval of the health ministry, tests on 500 human volunteers began in two 250-people sub-groups, and in this final phase a huge number of volunteers in Iran’s various provinces are involved.

The human trial of Razi-Covo Pars Covid19 Vaccine, which is the first Iranian injection-smelling new-formula protein Corona compound, has reached its final phase under the supervision of Agricultural Jihad Minister Kazem Khavazi, Head of Iranian Medical Science University Jalil Kouhpayeh, and a number of officials and researchers of Rasul-e Akram Hospital.

The method applied in the production of this vaccine is in accordance with the World Health Organization (WHO) routine.

The post Vaccine mass production line approved appeared first on Iran News Daily.